{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Inherited+Retinal+Disease+%28IRD%29",
    "query": {
      "condition": "Inherited Retinal Disease (IRD)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 9,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T08:13:34.262Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07502664",
      "title": "Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Retinitis Pigmentosa",
        "Stargardt Macular Dystrophy",
        "Stargardt Disease",
        "Geographic Atrophy From Age-related Macular Degeneration",
        "X-linked Retinoschisis",
        "Retinal Dystrophies"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Ray Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2026-02-19",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2026-03-31",
      "last_synced_at": "2026-05-22T08:13:34.262Z",
      "location_count": 1,
      "location_summary": "Irvine, California",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07502664"
    },
    {
      "nct_id": "NCT06445322",
      "title": "Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Stargardt Disease",
        "Stargardt Disease 1",
        "Cone Rod Dystrophy",
        "Juvenile Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Prescreening Assessments",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Ascidian Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "5 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2024-06-20",
      "completion_date": "2030-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-11",
      "last_synced_at": "2026-05-22T08:13:34.262Z",
      "location_count": 8,
      "location_summary": "San Francisco, California • Gainesville, Florida • Baltimore, Maryland + 5 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06445322"
    },
    {
      "nct_id": "NCT05616793",
      "title": "Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "LCA5"
      ],
      "interventions": [
        {
          "name": "AAV8.hLCA5",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Opus Genetics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "4 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2023-06-15",
      "completion_date": "2028-06-15",
      "has_results": false,
      "last_update_posted_date": "2026-02-19",
      "last_synced_at": "2026-05-22T08:13:34.262Z",
      "location_count": 2,
      "location_summary": "Philadelphia, Pennsylvania • Dallas, Texas",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05616793"
    },
    {
      "nct_id": "NCT06467344",
      "title": "Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Stargardt Disease",
        "Cone Rod Dystrophy",
        "Juvenile Macular Degeneration",
        "Stargardt Disease 1"
      ],
      "interventions": [
        {
          "name": "ACDN-01",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ascidian Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2024-06-11",
      "completion_date": "2030-12-01",
      "has_results": false,
      "last_update_posted_date": "2025-12-02",
      "last_synced_at": "2026-05-22T08:13:34.262Z",
      "location_count": 10,
      "location_summary": "San Francisco, California • Gainesville, Florida • Miami, Florida + 7 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06467344"
    },
    {
      "nct_id": "NCT02575430",
      "title": "Natural History Study in Inherited Retinal Disease Subjects Caused by Mutations in RPE65 or LRAT",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Leber Congenital Amaurosis (LCA)",
        "Retinitis Pigmentosa (RP)"
      ],
      "interventions": [
        {
          "name": "No treatment: retrospective chart review",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "QLT Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "8 Years and older"
      },
      "enrollment_count": 59,
      "start_date": "2015-12",
      "completion_date": "2016-03",
      "has_results": false,
      "last_update_posted_date": "2016-04-29",
      "last_synced_at": "2026-05-22T08:13:34.262Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Portland, Oregon",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02575430"
    },
    {
      "nct_id": "NCT05392751",
      "title": "Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Retinitis Pigmentosa",
        "Retinitis Pigmentosa Syndrome"
      ],
      "interventions": [
        {
          "name": "EA-2353",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Endogena Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2022-06-02",
      "completion_date": "2024-04-24",
      "has_results": false,
      "last_update_posted_date": "2024-10-15",
      "last_synced_at": "2026-05-22T08:13:34.262Z",
      "location_count": 5,
      "location_summary": "Miami, Florida • Ann Arbor, Michigan • Portland, Oregon + 2 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "McAllen",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05392751"
    },
    {
      "nct_id": "NCT06789445",
      "title": "A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Primary Photoreceptor Disease",
        "Retinitis Pigmentosa (RP)",
        "Usher Syndrome",
        "Inherited Retinal Disease (IRD)",
        "Rod-Cone Dystrophy",
        "Rod-Cone Disease",
        "Retinal Degeneration",
        "Cone-Rod Disease (C-RD)",
        "Cone-Rod Dystrophy"
      ],
      "interventions": [
        {
          "name": "OpCT-001",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "BlueRock Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2025-03-10",
      "completion_date": "2030-10",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-05-22T08:13:34.262Z",
      "location_count": 4,
      "location_summary": "Miami, Florida • Philadelphia, Pennsylvania • Dallas, Texas + 1 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06789445"
    },
    {
      "nct_id": "NCT05906953",
      "title": "Safety and Efficacy Trial of HG004 for Leber Congenital Amaurosis Related to Rpe65 Gene Mutations (STAR)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Leber Congenital Amaurosis",
        "Inherited Retinal Diseases Caused by RPE65 Mutations"
      ],
      "interventions": [
        {
          "name": "HG004",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "HuidaGene Therapeutics Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "6 Years to 50 Years"
      },
      "enrollment_count": 20,
      "start_date": "2023-10-31",
      "completion_date": "2025-12",
      "has_results": false,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-05-22T08:13:34.262Z",
      "location_count": 2,
      "location_summary": "Sacramento, California • Houston, Texas",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05906953"
    },
    {
      "nct_id": "NCT01521793",
      "title": "Repeated Treatments of QLT091001 in Subjects With Leber Congenital Amaurosis or Retinitis Pigmentosa (Extension of Study RET IRD 01)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "LCA (Leber Congenital Amaurosis)",
        "RP (Retinitis Pigmentosa)"
      ],
      "interventions": [
        {
          "name": "QLT091001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "QLT Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "5 Years to 65 Years"
      },
      "enrollment_count": 27,
      "start_date": "2012-01",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2014-07-28",
      "last_synced_at": "2026-05-22T08:13:34.262Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • Baltimore, Maryland",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01521793"
    }
  ]
}